- Headquarters: Karmiel, Israel
- Founded: 1993
- protalix.com
Protalix has licensed PRX-102 to Chiesi for all markets outside of the US, and Protalix will receive an upfront payment of $25 mln from Chiesi and additional payments of up to $25 million in development costs, capped at $10 million per year.
- Protalix is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone payments, and tiered royalties ranging from 15% to 35% on net sales.
- Protalix will continue to be the manufacturer of PRX-102 for clinical development purposes and commercial purposes after marketing approvals.
Description
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | 7.08% | -317.16% |
| Operating margin | -169.94% | -207.63% |
| EBITD margin | - | -338.95% |
| Return on average assets | 2.76% | -32.51% |
| Return on average equity | - | -6370.31% |
| Employees | 232 |
No comments:
Post a Comment